Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 430 | 78 | 347 |
| Samples | 410 | 74 | 334 |
| Peptides | 288 | 41 | 248 |
Function
NOX3 · NADPH oxidase 3
This gene encodes a member of the NOX family of NADPH oxidases. These enzymes have the capacity to generate superoxide and other reactive oxygen species (ROS) and transport electrons across the plasma membrane. The ROS generated by family members have been implicated in numerous biological functions including host defense, posttranlational processing of proteins, cellular signaling, regulation of gene expression, and cell differentiation. The protein encoded by this gene is expressed predominantly in the inner ear and is involved in the biogenesis of otoconia/otolith, which are crystalline structures of the inner ear involved in the perception of gravity.[provided by RefSeq, May 2009].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000159060 | Q9HBY0 | 430 | 288 |
Gene Properties
Recurrent Mutations
All 288 amino-acid changes on canonical ENST00000159060 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NOX3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NOX3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 19/304 6% | 28/1390 2% |
| Melanoma | 5/210 2% | 51/1899 3% |
| Endometrial Carcinoma | 1/42 2% | 15/612 2% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 14/810 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 13/752 2% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Other Solid Cancers | 1/94 1% | 23/1515 2% |
| Colorectal Carcinoma | 15/143 10% | 35/3239 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Gastric Carcinoma | 2/74 3% | 18/1809 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Head and Neck Carcinoma | 0/85 0% | 16/1574 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Bladder Carcinoma | 1/58 2% | 7/956 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 19/2550 1% |
| Biliary Tract Carcinoma | 2/54 4% | 5/950 1% |
| Neuroendocrine Tumour | 4/154 3% | 1/577 0% |
| Prostate Carcinoma | 0/13 0% | 13/2105 1% |
| Ovarian Carcinoma | 0/109 0% | 6/998 1% |
| Hepatocellular Carcinoma | 1/46 2% | 11/2210 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Glioma | 0/52 0% | 10/2127 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
Mutation Distribution
Where NOX3 is mutated · all tissues, split by cell line vs tissue
How many mutations in NOX3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 11 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 430 mutations in NOX3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|